Dizziness · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Adverse events at 1 month · adult participants with chronic blepharitis
It is very uncertain whether oral antibiotics changes adverse events at 1 month compared with placebo (very low certainty).
1 finding from 1 review
Adverse events: infection · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).
1 finding from 1 review
Adverse events: infection · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: infection compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dry mouth compared with placebo (high certainty).
1 finding from 1 review
Dysphagia · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dysphagia compared with placebo (high certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).
1 finding from 1 review
Adverse events: hypotension · type 1 or type 2 diabetics
Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).
1 finding from 1 review
Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All serious adverse events · children
Rotarix leads to lower all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).
1 finding from 1 review